|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Opinion: Atopic Dermatitis - A High Level of Unmet Need Creates Market Opportunities
Datamonitor, March 2007, Pages: 141
Atopic dermatitis is a skin disorder characterized by intense itch, dry skin and redness. Often considered a benign disease, it actually impacts very negatively on quality of life, sometimes more than psoriasis and diabetes. Through opinion leader interviews, we have identified a high level of unmet need in atopic dermatitis treatment and believe that a number of market opportunities exist
Scope of this title:
Understand opinion leaders views on hot issues in the atopic dermatitis market Assess the key unmet medical needs and identify specific opportunities in the atopic dermatitis market Examine epidemiological data for the prevalence of atopic dermatitis in the seven major markets (US, Japan, France, Germany, Italy, Spain, UK) Explore the current atopic dermatitis pipeline and identify leading products in development
Highlights of this title:
About 40 million patients suffer from atopic dermatitis in the seven major markets. There is a high level of unmet need and market opportunities exist for safer systemic therapies and effective drugs for itch. However, high drug cost will be a significant barrier to entry to the market and companies must also increase focus on patient education. Future entrants to the atopic dermatitis market will benefit from the strategies used by Novartis for Elidel such as a rapid global rollout and broad marketing campaign. Approval across all possible patient segments will ensure greatest sales potential. Choice of topical formulation is another important issue that companies must address. The late stage atopic dermatitis pipeline is empty and lacks innovation. In contrast, there are a number of Phase II products looking to fill the gap in the market for effective non-steroidal therapies, left by Protopic and Elidel. Despite a need for systemic therapies, we expect the overall demand for topical therapies will remain high.
Reasons to order your copy:
Review available treatments and understand major treatment controversies such as the safety of topical calcineurin inhibitors. Identify opportunities in the atopic dermatitis market and learn which strategies should be considered for success of future market entrants. Gain insight into the direction of future research for atopic dermatitis and learn what opinion leaders think of current pipeline products.
Customers who bought this item also bought
Atopic Dermatitis: Generic Erosion Leads to Stagnant Market
Pipeline and Commercial Perspectives: Psoriasis and Atopic Dermatitis - Reimbursement the key as biologics and TIMs transform disease markets
Dermatology Seborrheic Dermatitis
Seborrheic Dermatitis Therapy Area Pipeline Report
Psoriasis - Biologics are Yet to Make Topical Treatments Obsolete
The Dermatology Market Outlook to 2013: Competitive Landscape, Pipeline Analysis and Growth Opportunities
The Dermatology Market Outlook to 2011
Psoriasis - Biologics Impact Treatment Regimes Across The Globe
Update on Dermatology Market
Stakeholder Opinions: Systemic Lupus Erythematosus - Market Set to Enter Era of Biologic Therapies
Commercial Insight: Psoriasis - Intellectual property drives growth
U.S. Market for Psoriasis Cream and Medication 2009
|
|
|
|
